中国新诊断2型糖尿病患者肠促胰岛素研究现状  

Study on the Intestinal Promoting Insulin in Newly Diagnosed Type 2 Diabetic Patients in China

作　　者：王徐溢[1] 孙子林[1] 

机构地区：[1]东南大学附属中大医院内分泌科,江苏南京210009

出　　处：《药品评价》2016年第9期12-15,20,共5页Drug Evaluation

摘　　要：2型糖尿病是21世纪慢性病防治的巨大挑战之一。良好的血糖控制可以避免或延缓大血管及微血管并发症的发生及进展。基于肠促胰岛素类药物(如GLP-1受体激动剂、DPP-4抑制剂)具有降低体重、降低低血糖发生率以及改善胰腺β细胞功能等优势,肠促胰岛素已成为近年来研究热点。肠促胰岛素包括胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)和葡萄糖依赖性促胰岛素分泌多肽(glucose-dependent insulinotropic polypeptide,GIP)。本文将对肠促胰岛素在中国新诊断2型糖尿病患者中的研究进展进行综述。Type 2 diabetes represents one of the most important chronic disease challenges of the 21 st century. Early intervention to prevent and limit progression of micro- and macro-vascular complications can be achieved with good glycaemic control. The research and clinical application or the incretin have been made rapid progresses in recent years because of unique mechanism of action of incretin drugs such as promoting weight loss, reducing hypoglycemia incidence rate and improvingβ-cell function. The incretin include glucagon-like peptide-1（GLP-1） and glucose-dependent insulinotropic polypeptide（GIP）. So, this review describes the research progress of incretin in newly diagnosed Chinese type 2 diabetes mellitlls.

关 键 词：新诊断2型糖尿病 肠促胰岛素 胰高血糖素样肽-1(GLP-1) 葡萄糖依赖性促胰岛素分泌多肽(GIP) 

分 类 号：R587.1[医药卫生—内分泌]